References
- Allegra, C., Blanke, C., Buyse, M., Goldberg, R., Grothey, A., Meropol, N. J., Saltz, L., Venook, A., Yothers, G., and Sargent, D. (2007), “End Points in Advanced Colon Cancer Clinical Trials: A Review and Proposal,” Journal of Clinical Oncology, 25, 3572–3575. DOI: https://doi.org/10.1200/JCO.2007.12.1368.
- Asakura, K., Hamasaki, T., and Evans, S. R. (2017), “Interim Evaluation of Efficacy or Futility in Group-Sequential Trials With Multiple Co-Primary Endpoints,” Biometrical Journal, 59, 703–731. DOI: https://doi.org/10.1002/bimj.201600026.
- Chibaudel, B., Bonnetain, F., Shi, Q., Buyse, M., Tournigand, C., Sargent, D. J., Allegra, C. J., Goldberg, R. M., and de Gramont, A. (2011), “Alternative End Points to Evaluate a Therapeutic Strategy in Advanced Colorectal Cancer: Evaluation of Progression-Free Survival, Duration of Disease Control, and Time to Failure of Strategy—An Aide et Recherche en Cancérologie Digestive Group Study,” Journal of Clinical Oncology, 29, 4199–4204. DOI: https://doi.org/10.1200/JCO.2011.35.5867.
- Collett, D. (1994), Modelling Survival Data in Medical Research, Texts in Statistical Science, London: Chapman & Hall.
- Fleischer, F., Gaschler-Markefski, B., and Bluhmki, E. (2009), “A Statistical Model for the Dependence Between Progression-Free Survival and Overall Survival,” Statistics in Medicine, 28, 2669–2686. DOI: https://doi.org/10.1002/sim.3637.
- Freidlin, B., and Korn, E. L. (2009), “Monitoring for Lack of Benefit: A Critical Component of a Randomized Clinical Trial,” Journal of Clinical Oncology, 27, 629. DOI: https://doi.org/10.1200/JCO.2008.17.8905.
- Freidlin, B., and Korn, E. L. (2002), “A Comment on Futility Monitoring,” Controlled Clinical Trials, 23, 355–366.
- Freidlin, B., Korn, E. L., and Gray, R. (2010), “A General Inefficacy Interim Monitoring Rule for Randomized Clinical Trials,” Clinical Trials, 7, 197–208. DOI: https://doi.org/10.1177/1740774510369019.
- Freidlin, B., Little, R. F., and Korn, E. L. (2015), “Design Issues in Randomized Clinical Trials of Maintenance Therapies,” Journal of the National Cancer Institute, 107, djv225. DOI: https://doi.org/10.1093/jnci/djv225.
- Gallo, P., Mao, L., and Shih, V. H. (2014), “Alternative Views on Setting Clinical Trial Futility Criteria,” Journal of Biopharmaceutical Statistics, 24, 976–993. DOI: https://doi.org/10.1080/10543406.2014.932285.
- Glimm, E., Maurer, W., and Bretz, F. (2010), “Hierarchical Testing of Multiple Endpoints in Group-Sequential Trials,” Statistics in Medicine, 29, 219–228. DOI: https://doi.org/10.1002/sim.3748.
- Goldman, B., LeBlanc, M., and Crowley, J. (2008), “Interim Futility Analysis With Intermediate Endpoints,” Clinical Trials, 5, 14–22. DOI: https://doi.org/10.1177/1740774507086648.
- Gou, J., and Xi, D. (2019), “Hierarchical Testing of a Primary and a Secondary Endpoint in a Group Sequential Design With Different Information Times,” Statistics in Biopharmaceutical Research, 11, 398–406. DOI: https://doi.org/10.1080/19466315.2018.1546613.
- Hamasaki, T., Sugimoto, T., Evans, S., and Sozu, T. (2013), “Sample Size Determination for Clinical Trials With Co-Primary Outcomes: Exponential Event Times,” Pharmaceutical Statistics, 12, 28–34. DOI: https://doi.org/10.1002/pst.1545.
- Hunsberger, S., Zhao, Y., and Simon, R. (2009), “A Comparison of Phase II Study Strategies,” Clinical Cancer Research, 15, 5950–5955. DOI: https://doi.org/10.1158/1078-0432.CCR-08-3205.
- Jennison, C., and Turnbull, B. W. (1999), Group Sequential Methods With Applications to Clinical Trials, Boca Raton, FL: Chapman and Hall/CRC.
- Lachin, J. M. (2010), Biostatistical Methods: The Assessment of Relative Risks, Wiley Series in Probability and Statistics (2nd ed.), Hoboken, NJ: Wiley.
- Lan, G. K., and DeMets, D. L. (1983), “Discrete Sequential Boundaries for Clinical Trials,” Biometrika, 70, 659–663. DOI: https://doi.org/10.2307/2336502.
- Nelsen, R. B. (2007), An Introduction to Copulas, New York: Springer-Verlag.
- Nomura, S., Goto, Y., Mizutani, T., Kataoka, T., Kawai, S., Okuma, Y., Murakami, H., Tanaka, K., and Ohe, Y. (2020), “A Randomized Phase III Study Comparing Continuation and Discontinuation of PD-1 Pathway Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer (JCOG1701, SAVE Study),” Japanese Journal of Clinical Oncology. DOI: https://doi.org/10.1093/jjco/hyaa054.
- Nomura, S., Hirakawa, A., and Hamada, C. (2018), “Sample Size Determination for the Current Strategy in Oncology Phase 3 Trials That Tests Progression-Free Survival and Overall Survival in a Two-Stage Design Framework,” Journal of Biopharmaceutical Statistics, 28, 589–611. DOI: https://doi.org/10.1080/10543406.2017.1372775.
- Schoenfeld, D. A. (1983), “Sample-Size Formula for the Proportional-Hazards Regression Model,” Biometrics, 39, 499–503. DOI: https://doi.org/10.2307/2531021.
- Schoenfeld, D. A., and Richter, J. R. (1982), “Nomograms for Calculating the Number of Patients Needed for a Clinical Trial With Survival as an Endpoint,” Biometrics, 38, 163–170. DOI: https://doi.org/10.2307/2530299.
- Snapinn, S., Chen, M.-G., Jiang, Q., and Koutsoukos, T. (2006), “Assessment of Futility in Clinical Trials,” Pharmaceutical Statistics, 5, 273–281. DOI: https://doi.org/10.1002/pst.216.
- Sugimoto, T., Hamasaki, T., Evans, S. R., and Halabi, S. (2020), “Group-Sequential Logrank Methods for Trial Designs Using Bivariate Non-Competing Event-Time Outcomes,” Lifetime Data Analysis, 26, 266–291. DOI: https://doi.org/10.1007/s10985-019-09470-4.
- Sugimoto, T., Hamasaki, T., Evans, S. R., and Sozu, T. (2017), “Sizing Clinical Trials When Comparing Bivariate Time-to-Event Outcomes,” Statistics in Medicine, 36, 1363–1382. DOI: https://doi.org/10.1002/sim.7225.
- Sugimoto, T., Sozu, T., Hamasaki, T., and Evans, S. R. (2013), “A Logrank Test-Based Method for Sizing Clinical Trials With Two Co-Primary Time-to-Event Endpoints,” Biostatistics, 14, 409–421. DOI: https://doi.org/10.1093/biostatistics/kxs057.
- Tamhane, A. C., Mehta, C. R., and Liu, L. (2010), “Testing a Primary and a Secondary Endpoint in a Group Sequential Design,” Biometrics, 66, 1174–1184. DOI: https://doi.org/10.1111/j.1541-0420.2010.01402.x.
- Togo, K., and Iwasaki, M. (2013), “Optimal Timing for Interim Analyses in Clinical Trials,” Journal of Biopharmaceutical Statistics, 23, 1067–1080. DOI: https://doi.org/10.1080/10543406.2013.813522.
- Tsiatis, A. A. (1982), “Repeated Significance Testing for a General Class of Statistics Used in Censored Survival Analysis,” Journal of the American Statistical Association, 77, 855–861. DOI: https://doi.org/10.1080/01621459.1982.10477898.
- Wang, M., Dignam, J. J., Zhang, Q. E., DeGroot, J. F., Mehta, M. P., and Hunsberger, S. (2012), “Integrated Phase II/III Clinical Trials in Oncology: A Case Study,” Clinical Trials, 9, 741–747. DOI: https://doi.org/10.1177/1740774512464724.
- Xi, D., Gallo, P., and Ohlssen, D. (2017), “On the Optimal Timing of Futility Interim Analyses,” Statistics in Biopharmaceutical Research, 9, 293–301. DOI: https://doi.org/10.1080/19466315.2017.1340906.
- Zhang, Q., Freidlin, B., Korn, E. L., and Dignam, J. (2011), “Comparison of Futility Monitoring Methods Using RTOG Clinical Trials,” Clinical Trials, 68. DOI: https://doi.org/10.1177/1740774516666502.
- Zhang, Q., Freidlin, B., Korn, E. L., Halabi, S., Mandrekar, S., and Dignam, J. J. (2017), “Comparison of Futility Monitoring Guidelines Using Completed Phase III Oncology Trials,” Clinical Trials, 14, 48–58. DOI: https://doi.org/10.1177/1740774516666502.